1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Generics in Turkey

Generics in Turkey

  • January 2017
  • -
  • MarketLine
  • -
  • 30 pages

Summary
Generics in Turkey industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Key Findings
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Turkey
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Turkey
- Leading company profiles reveal details of key generics market players' global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the Turkey generics market with five year forecasts by both value and volume

Synopsis
Essential resource for top-line data and analysis covering the Turkey generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Reasons To Buy
- What was the size of the Turkey generics market by value in 2016?
- What will be the size of the Turkey generics market in 2021?
- What factors are affecting the strength of competition in the Turkey generics market?
- How has the market performed over the last five years?
- How large is Turkey's generics market in relation to its regional counterparts?

Key Findings
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Turkish generics market is expected to generate total revenues of $1.8bn in 2016, representing a compound annual growth rate (CAGR) of 6.2% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 0.1% between 2012 and 2016, to reach a total of 51.4% of total pharma volume in 2016.

In 2012, the Turkish government decided to provide free access to healthcare services for those earning less than roughly $150 per month, whilst those earning more paid a social security premium.

Table Of Contents

Generics in Turkey
Table of Contents
Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Abdi Ibrahim Ilac Sanayi ve Ticaret AS
DEVA Holding
Nobel Pharmaceuticals
Sandoz International GmbH
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine

List of Tables
Table 1: Turkey generics market value: $ billion, 2012-16(e)
Table 2: Turkey generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Turkey generics market geography segmentation: $ billion, 2016(e)
Table 4: Turkey generics market value forecast: $ billion, 2016-21
Table 5: Turkey generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Abdi Ibrahim Ilac Sanayi ve Ticaret AS: key facts
Table 7: DEVA Holding: key facts
Table 8: DEVA Holding: key financials ($)
Table 9: DEVA Holding: key financials (TL)
Table 10: DEVA Holding: key financial ratios
Table 11: Nobel Pharmaceuticals: key facts
Table 12: Sandoz International GmbH: key facts
Table 13: Turkey size of population (million), 2012-16
Table 14: Turkey gdp (constant 2005 prices, $ billion), 2012-16
Table 15: Turkey gdp (current prices, $ billion), 2012-16
Table 16: Turkey inflation, 2012-16
Table 17: Turkey consumer price index (absolute), 2012-16
Table 18: Turkey exchange rate, 2012-16

List of Figures
Figure 1: Turkey generics market value: $ billion, 2012-16(e)
Figure 2: Turkey generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Turkey generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Turkey generics market value forecast: $ billion, 2016-21
Figure 5: Turkey generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Turkey, 2016
Figure 7: Drivers of buyer power in the generics market in Turkey, 2016
Figure 8: Drivers of supplier power in the generics market in Turkey, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Turkey, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Turkey, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Turkey, 2016
Figure 12: DEVA Holding: revenues and profitability
Figure 13: DEVA Holding: assets and liabilities

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • December 2016
  • by GlobalData

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the ...

PharmaFocus: Tauopathies - Global Market Analysis

PharmaFocus: Tauopathies - Global Market Analysis

  • $ 9495
  • Industry report
  • February 2017
  • by GlobalData

PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...


ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.